Table 2.
CRS/HIPEC and postoperative characteristics by stage.
| Characteristic | Total population (n = 27) | Stage III (n = 12) | Stage IV (n = 15) | p value |
|---|---|---|---|---|
| CRS/HIPEC characteristics | ||||
| Median time from NACT to CRS/HIPEC [IQR], days | 40 [35–45] | 41 [30–47] | 40 [35–45] | 0.757 |
| Median PCI [IQR] | 20 [12–27] | 21 [10–29] | 20 [13–26] | 0.926 |
| Extent of resections, median [IQR] | ||||
| Organs resected | 7 [5–8] | 6 [5–8] | 7 [6–8] | 0.490 |
| Visceral peritonectomies | 2 [2-3] | 2 [1–3] | 2 [2-3] | 0.409 |
| Parietal peritonectomies | 4 [3-4] | 4 [3-4] | 4 [3–5] | 0.504 |
| Pelvic mass, n (%) | 24 (89) | 9 (75) | 15 (100) | 0.075 |
| Bowel anastomosis, n (%) | ||||
| 0 | 5 (19) | 3 (25) | 2 (13) | — |
| 1 | 13 (48) | 5 (42) | 8 (53) | — |
| 2 | 9 (33) | 4 (33) | 5 (33) | — |
| CC score, n (%) | ||||
| CC-0 (no visible tumor) | 22 (81) | 8 (67) | 14 (93) | — |
| CC-1 (tumor ≤0.25 cm) | 4 (15) | 3 (25) | 1 (7) | — |
| CC-2 (tumor 0.25 cm–2.5 cm) | 1 (4) | 1 (8) | 0 (0) | — |
| Median length of surgery [IQR], hours | 8 [7–8] | 8.3 [6.4–9.3] | 8 [7–8.3] | 0.482 |
| Estimated blood loss [IQR], mL | 500 [350–800] | 425 [275–600] | 600 [350–1000] | 0.170 |
| Transfusions, n (%) | ||||
| Intraoperative | 16 (59) | 7 (58) | 9 (60) | 1.000 |
| Postoperative | 21 (78) | 7 (58) | 14 (93) | 0.060 |
| Median length of hospitalization [IQR], days | 9 [7–11] | 8 [6–9] | 11 [8–12] | 0.010 |
| Tumor site, n (%) | ||||
| Ovary | 9 (33) | 4 (33) | 5 (33) | — |
| Fallopian tube | 11 (41) | 4 (33) | 7 (47) | — |
| Primary peritoneal | 7 (26) | 4 (33) | 3 (20) | — |
|
| ||||
| Postoperative characteristics | ||||
| Grade III/IV surgical complications, n (%) | 3 (11) | 0 (0) | 3 (23) | — |
| Hematologic toxicity, n (%) | ||||
| Anemia | ||||
| Preoperative | 22 (82) | 10 (83) | 11 (73) | 0.662 |
| Postoperative | 27 (100) | 12 (100) | 15 (100) | — |
| Leukopenia | ||||
| Preoperative | 10 (37) | 6 (50) | 4 (27) | 0.257 |
| Postoperative | 10 (37) | 3 (25) | 7 (47) | 0.424 |
| Thrombocytopenia | ||||
| Preoperative | 1 (4) | 0 (0) | 1 (7) | 1.000 |
| Postoperative | 19 (70) | 7 (58) | 12 (80) | 0.398 |
| Median CA-125 post-CRS/HIPEC [IQR] (n), U/mL | 13 [8.2–23.2] | 17 [8.2–28.6] (10) | 13 [7.3–21.9] (12) | 0.767 |
| Positive lymph nodes, n (%) | 17/26 (65) | 7/11 (63) | 10 (67) | 0.706 |
| Patients with ASC, n (%) | 21 (78) | 11 (92) | 10 (67) | 0.182 |
| Median time from CRS/HIPEC to ASC [IQR], days | 57 [51–73] | 53 [40–58] | 74 [56–91] | 0.007 |
| Median CA-125 post-ASC [IQR] (n), U/mL | 9.5 [7–13] | 11 [7–18.2] (11) | 9 [7.3–12.3] (8) | 0.385 |
| Recurrence, n (%) | 21 (81) | 9/11 (81) | 12 (80) | 0.236 |
| Alive, n (%) | 15 (55) | 5 (42) | 10 (67) | — |
| Median follow-up (95% CI), months | 31 [22–40] | 31 [23–39] | 30 [14–46] | — |
ASC: adjuvant systemic chemotherapy, CC: completeness of cytoreduction score, CI: confidence interval, CRS/HIPEC: cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, IQR: interquartile range, NACT: neoadjuvant chemotherapy.